AlloVir (NASDAQ:ALVR) Trading 8.2% Higher – Here’s What Happened

AlloVir, Inc. (NASDAQ:ALVR) shares were up 8.2% during mid-day trading on Friday . The stock traded as high as $9.50 and last traded at $9.74. 34,835 shares changed hands during trading, a decline of 2% from the average daily volume of 35,517 shares. The stock had previously closed at $9.00.

AlloVir Trading Up 4.9 %

The company has a market capitalization of $1.09 billion, a PE ratio of -10.73 and a beta of 0.65. The business has a fifty day moving average of $0.67 and a 200 day moving average of $0.74.

AlloVir (NASDAQ:ALVR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10.

Institutional Trading of AlloVir

A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC boosted its stake in shares of AlloVir, Inc. (NASDAQ:ALVR) by 152.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,816 shares of the company’s stock after purchasing an additional 30,072 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent SEC filing. Institutional investors own 66.05% of the company’s stock.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.